CNS effects of sumatriptan and rizatriptan in healthy female volunteers

Cephalalgia

Volumn 22, Issue 4, 2002, Pages 271-281

  Van Der Post, J ^a   Schram, M T ^a   Schoemaker, R C ^a   Pieters, M S M ^a   Fuseau, E ^c   Pereira, A ^b   Baggen, S ^b   Cohen, A F ^a   Van Gerven, J M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c EMF Consulting   (France)

Author keywords

Cognitive function; EEG; Eye movements; Rizatriptan; Sumatriptan

Indexed keywords

RIZATRIPTAN; SUMATRIPTAN; TEMAZEPAM; HTR1B PROTEIN, HUMAN; HYPNOTIC SEDATIVE AGENT; NERVE PROTEIN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; TRIAZOLE DERIVATIVE; TRYPTAMINE DERIVATIVE;

ARTICLE; BODY EQUILIBRIUM; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ELECTROENCEPHALOGRAM; EYE MOVEMENT; FEMALE; HUMAN; NERVE STIMULATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SACCADIC EYE MOVEMENT; SEDATION; VISUAL ANALOG SCALE; ADULT; AFFECT; BRAIN; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DIZZINESS; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; HEADACHE; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; RECOGNITION; REFERENCE VALUE;

ADULT; AFFECT; BRAIN; COGNITION; CROSS-OVER STUDIES; DIZZINESS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EYE MOVEMENTS; FEMALE; HEADACHE; HUMANS; HYPNOTICS AND SEDATIVES; MUSCULOSKELETAL EQUILIBRIUM; NERVE TISSUE PROTEINS; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; RECOGNITION (PSYCHOLOGY); REFERENCE VALUES; SEROTONIN AGONISTS; SUMATRIPTAN; TEMAZEPAM; TRIAZOLES; TRYPTAMINES;

EID: 0036559362     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2002.00344.x     Document Type: Article

References (44)

1. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials. Cephalalgia 1993; 13 (4):238-44.
2. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995; 47 (6):543-8.
3. Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998; 6 (2):99-104.
4. Cheng H, Polvino WJ, Sciberras D, Yogendran L, Cerchio KA, Christie K et al. Pharmacokinetics and food interaction of MK-462 in healthy males. Biopharm Drug Dispos 1996; 17 (1):17-24.
5. Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J et al. Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist [published erratum appears in Br J Clin Pharmacol 1997;43 (4):450]. Br J Clin Pharmacol 1997; 43 (1):49-54.
6. Cutler NR, Claghorn J, Sramek JJ, Block G, Panebianco D, Cheng H et al. Pilot study of MK-462 in migraine. Cephalalgia 1996; 16 (2):113-6.
7. Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache 1998; 38 (4):281-7.
8. Gijsman H, Kramer MS, Sargent J, Tuchman M, Matzura-Wolfe D, Polis A et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17 (6):647-51.
9. Harron DW, Hasson B, Regan M, McClelland RJ, King DJ. Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function. J Cardiovasc Pharmacol 1995; 26 (Suppl.):S48-54.
10. van Steveninck AL, Wallnofer AE, Schoemaker RC, Pieters MS, Danhof M, van Gerven JM et al. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 1997; 44 (3):267-75.
11. Wright BM. A simple mechanical ataxia-meter. J Physiol 1971; 218 (1):27P-8.
12. van Steveninck AL, Cohen AF, Ward T. A microcomputer based system for recording and analysis of smooth pursuit and saccadic eye movements. Br J Clin Pharmacol 1989; 27 (5):712-3.
13. Steveninck A, Lv Berckel BN, Mv Schoemaker HC, Breimer DD, Gerven JM, Av Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharm 1999; 13 (1):10-7.
14. Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 1971; 10 (21):181-91.
15. Bond A, Lader M. Self-concepts in anxiety states. Br J Med Psychol 1976; 49 (3):275-9.
16. Moerland M, Aldenkamp AP, Alpherts WCJ. A neuropsychological test battery for the apple II-E. Intern J Man-Machine Studies 1986; 25:453-67.
17. Alpherts WC, Aldenkamp AP. Computerized neuropsychological assessment of cognitive functioning in children with epilepsy. Epilepsia 1990; 31 (Suppl. 4):S35-40.
18. Aldenkamp AP, Arends J, Overweg-Plandsoen TC, van Bronswijk KC, Schyns-Soeterboek A, Linden I et al. Acute cognitive effects of nonconvulsive difficult-to-detect epileptic seizures and epileptiform electroencephalographic discharges. J Child Neurol 2001; 16 (2):119-23.
19. Goldstein G, Welch RB, Rennick PM, Shelly CH. The validity of a visual searching task as an indicator of brain damage. J Consult Clin Psychol 1973; 41 (3):434-7.
20. DeMita MA, Johnson JH. The validity of a computerized visual searching task as an indicator of brain damage. Behav Res Meth Instrumentation 1981; 13:592-4.
21. Anderson SW, Damasio H, Jones RD, Tranel D. Wisconsin Card Sorting Test performance as a measure of frontal lobe damage. J Clin Exp Neuropsychol 1991; 13 (6):909-22.
22. Nelson RE, Dickson AL, Banos JH. An automated administration of Corsi's Block-tapping Test. Percept Mot Skills 2000; 91 (2):578-80.
23. Lee Y, Conroy JA, Stepanavage ME, Mendel CM, Somers G, McLoughlin DA et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol 1999; 47 (4):373-8.
24. Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001; 40 (3):189-205.
25. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31 (5):291-4.
26. van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 1991; 50 (2):172-80.
27. Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991; 31 (5):282-90.
28. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358 (9294):1668-75.
29. Kleidienst-Vanderbeke O. Psychopharmacology and Reaction Time. Chichester: John Wiley, 1998.
30. Ray WJ, Cole HW. EEG activity during cognitive processing: influence of attentional factors. Int J Psychophysiol 1985; 3 (1):43-8.
31. Cole HW, Ray WJ. EEG correlates of emotional tasks related to attentional demands. Int J Psychophysiol 1985; 3 (1):33-41.
32. Valentino DA, Dufresne RL. Attention tasks and EEG power spectra. Int J Psychophysiol 1991; 11 (3):299-301.
33. Lindsey DB. Attention, consciousness, sleep & wakefulness. In: Field J, Magoun HW, Hall E, eds. Handbook of Physiology. Washington, DC: American Physiological Society, 1960:1553-93.
34. van Steveninck AL, Schoemaker HC, den Hartigh J, Pieters MS, Breimer DD, Cohen AF. Effects of intravenous temazepam. II. A study of the long-term reproducibility of pharmacokinetics, pharmacodynamics, and concentration-effect parameters. Clin Pharmacol Ther 1994; 55 (5):546-55.
35. van Steveninck AL, Schoemaker HC, den Hartigh J, Rijnkels J, Pieters MS, Breimer DD et al. Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state. Clin Pharmacol Ther 1994; 55 (5):535-45.
36. van Steveninck AL, Mandema JW, Tuk B, Van Dijk JG, Schoemaker HC, Danhof M et al. A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity. Br J Clin Pharmacol 1993; 36 (2):109-15.
37. Holland RL, Wesnes K, Dietrich B. Single dose human pharmacology of umespirone. Eur J Clin Pharmacol 1994; 46 (5):461-8.
38. Lucki I, Rickels K, Giesecke MA, Geller A. Differential effects of the anxiolytic drugs, diazepam and buspirone, on memory function. Br J Clin Pharmacol 1987; 23 (2):207-11.
39. Alford C, Bhatti JZ, Curran S, McKay G, Hindmarch I. Pharmacodynamic effects of buspirone and clobazam. Br J Clin Pharmacol 1991; 32 (1):91-7.
40. Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32 (2):114-29.
41. Bourin M, Auget JL, Colombel MC, Larousse C. Effects of single oral doses of bromazepam, buspirone and clobazam on performance tasks and memory. Neuropsychobiology 1989; 22 (3):141-5.
42. Proietti-Cecchini A, Afra J, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia 1997; 17 (8):849-54.
43. Read SJ, Parsons AA. Sumatriptan modifies cortical free radical release during cortical spreading depression. A novel antimigraine action for sumatriptan? Brain Res 2000-870 (1-2):44-53.
44. Thomaides T, Tagaris G, Karageorgiou C. EEG and topographic frequency analysis in migraine attack before and after sumatriptan infusion. Headache 1996; 36 (2):111-4.